跳至主要内容
临床试验/JPRN-UMIN000005736
JPRN-UMIN000005736尚未招募未知

Study of establishment of myoblasts derived muscle tissue of muscular dystrophy patients - Establishment of myoblasts derived muscle tissue of muscular dystrophy patients

Department of Pediatrics, Kobe University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2011年9月1日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • no exclusion criteria

研究者

发起方
Department of Pediatrics, Kobe University Graduate School of Medicine

相似试验

已完成
不适用
Training of intramuscular connective tissue in elderlyM62.5M62.9Muscle wasting and atrophy, not elsewhere classifiedDisorder of muscle, unspecified
DRKS00015750Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik56
已完成
不适用
Tissue Donation for Myoblast CultureObserve in Vitro Characteristics of Muscle TissueElective Obstetric or Gynecologic Surgery
NCT01119820University of California, Irvine24
暂停
3 期
Implement of Autologous Skeletal Myoblast Cell Sheet Transplantation for Dilated Cardio myopathy aiming Precision Medicine (Imple ment of Autologous Skeletal Myoblast Cell Sheet Transplantation for Dilated Cardiomyo pathy aiming Precision Medicine)dilated cardiomyopathy
JPRN-jRCTb050200131miyagawa shigeru4
已完成
不适用
The investigation for the improvement of muscle mass and muscle strength using a branched-chain amino acid (BCAA)-enriched nutrient (Aminoleban EN) in patients with liver cirrhosis associated with liver encephalopathydecompensated liver cirrhosis
JPRN-UMIN000018278shonan kamakura general hospital100
进行中(未招募)
1 期
The aim of this clinical study is to show the clinical efficacy and safety of SMDCs in patients suffering from FI, and to find the optimal cell count for the functional regeneration of the external anal sphincter.Fecal incontinence in female and male patients.MedDRA version: 17.0Level: LLTClassification code 10016296Term: Fecal incontinenceSystem Organ Class: 100000004856
EUCTR2010-021463-32-BGInnovacell Biotechnologie AG252